tetano
Editor, Senior Moderator
Lancet Infect Dis
. 2026 Jul 28:S1473-3099(26)00255-0.
doi: 10.1016/S1473-3099(26)00255-0. Online ahead of print.
Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial
Podjanee Jittamala[SUP] 1 [/SUP], William H K Schilling[SUP] 2 [/SUP], Stije J Leopold[SUP] 3 [/SUP], James A Watson[SUP] 4 [/SUP], Kantapong Kotchum[SUP] 5 [/SUP], Phrutsamon Wongnak[SUP] 5 [/SUP], Timothy Seers[SUP] 5 [/SUP], Tanatchakorn Asawasriworanan[SUP] 5 [/SUP], Shivani Singh[SUP] 5 [/SUP], Ellen Beer[SUP] 5 [/SUP], Thatsanun Ngernseng[SUP] 5 [/SUP], Kanokon Suwannasin[SUP] 5 [/SUP], Wanassanan Madmanee[SUP] 5 [/SUP], Koukeo Phommasone[SUP] 6 [/SUP], Suchita Shrestha[SUP] 7 [/SUP], Renato Santana de Aguiar[SUP] 8 [/SUP], Elizabeth M Batty[SUP] 2 [/SUP], Mauro M Teixeira[SUP] 9 [/SUP], Abhilasha Karkey[SUP] 7 [/SUP], Elizabeth A Ashley[SUP] 10 [/SUP], Poj Intalapaporn[SUP] 11 [/SUP], Viravarn Luvira[SUP] 12 [/SUP], Weerapong Phumratanaprapin[SUP] 12 [/SUP], Kesinee Chotivanich[SUP] 13 [/SUP], Mallika Imwong[SUP] 14 [/SUP], Nicholas J White[SUP] 2 [/SUP]; AD ASTRA Collaborative Group
Affiliations
Background: The oral antiviral therapies baloxavir marboxil (hereafter baloxavir), favipiravir, and oseltamivir have not been simultaneously compared for the treatment of seasonal influenza. We aimed to determine their relative efficacies in accelerating viral clearance in patients with symptomatic influenza virus infection at low risk of progression to severe disease.
Methods: We conducted a phase 2, open-label, randomised, controlled, adaptive platform trial in patients aged 18-60 years in Thailand, Laos, Nepal, and Brazil, recruited in four hospital outpatient or primary care departments with acute influenza (≤ 4 days of symptoms) and a low risk of progression to severe disease. Patients were randomly assigned 1:1:1:1:1 using a centralised online app to receive baloxavir (single oral dose of 40 mg if bodyweight <80 kg or 80 mg if bodyweight ≥80 kg), favipiravir (oral loading dose of 1800 mg, followed by 1800 mg 12 h later, and then 800 mg twice daily for 4 days), oseltamivir (oral dose 75 mg twice daily for 5 days), no study drug, or another ongoing intervention (reported separately). Randomisation was stratified by site and used block sizes of 15. The primary endpoint was the rate of oropharyngeal influenza viral RNA clearance, estimated under a Bayesian hierarchical linear model fitted to the daily log[SUB]10[/SUB] oropharyngeal viral densities from day 0 to day 5. Analyses were conducted in the modified intention-to-treat population (mITT), defined as patients with PCR-confirmed influenza with more than 250 viral RNA copies per mL at randomisation. Intervention groups were assessed for superiority over the no study drug group (posterior probability >0·9 that the relative increase in viral clearance was ≥20%); if superiority was met, intervention groups were assessed for non-inferiority relative to baloxavir (posterior probability >0·9 that the relative reduction in viral clearance was ≤10%). Secondary outcomes included time to resolution of fever and time to resolution of all symptoms. The trial is registered with ClinicalTrials.gov (NCT05648448) and is ongoing.
Findings: Between Feb 22, 2023, and Dec 12, 2025, 944 patients with influenza virus infection were randomly assigned to baloxavir (n=199; mITT 163 [82%]), favipiravir (n=223; mITT 196 [88%]), oseltamivir (n=200; mITT 170 [85%]), no study drug (n=228; mITT 200 [88%]) or other interventions (n=94). 120 patients were excluded based on baseline viral density (≤250 copies per mL), and one participant withdrew before collection of quantitative PCR results on day 0. 457 (63%) patients in the mITT population were female and 272 (37%) were male. Compared with no study drug, viral clearance rates were accelerated by 86% (95% credible interval [CrI] 60-117) with baloxavir, 66% (45-94) with favipiravir, and 49% (28-74) with oseltamivir. For all interventions, the posterior probability that the relative increase in viral clearance was 20% or more was 1·0. Compared with baloxavir, oseltamivir was inferior (20% slower clearance, 95% CrI 6 to 32; posterior probability 0·93 that the relative reduction in viral clearance was <10%); non-inferiority could not be shown for favipiravir (10% slower clearance, 95% CrI -4 to 22; posterior probability 0·55 that the relative reduction in viral clearance was <10%). Median time to fever resolution was accelerated with all three antivirals compared with no study drug (absolute differences ranging from 0·5 days to 0·9 days), whereas time to resolution of all symptoms was not significantly different between groups. 31 adverse events of grade 3 or above occurred, five of which were considered severe (one in the favipiravir group, one in the oseltamivir group, and three in the no study drug group).
Interpretation: Oral baloxavir, favipiravir, and oseltamivir accelerated influenza viral clearance rates in adults with early non-severe seasonal influenza at low risk of progression to severe disease. Baloxavir had the greatest in-vivo antiviral efficacy, followed by favipiravir and oseltamivir. These antivirals shortened fever duration but showed no clear effects on time to complete symptom resolution. This pharmacometric approach can inform prioritisation of antiviral agents for further study and potential inclusion in pandemic stockpiles.
Funding: Wellcome Trust.
. 2026 Jul 28:S1473-3099(26)00255-0.
doi: 10.1016/S1473-3099(26)00255-0. Online ahead of print.
Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial
Podjanee Jittamala[SUP] 1 [/SUP], William H K Schilling[SUP] 2 [/SUP], Stije J Leopold[SUP] 3 [/SUP], James A Watson[SUP] 4 [/SUP], Kantapong Kotchum[SUP] 5 [/SUP], Phrutsamon Wongnak[SUP] 5 [/SUP], Timothy Seers[SUP] 5 [/SUP], Tanatchakorn Asawasriworanan[SUP] 5 [/SUP], Shivani Singh[SUP] 5 [/SUP], Ellen Beer[SUP] 5 [/SUP], Thatsanun Ngernseng[SUP] 5 [/SUP], Kanokon Suwannasin[SUP] 5 [/SUP], Wanassanan Madmanee[SUP] 5 [/SUP], Koukeo Phommasone[SUP] 6 [/SUP], Suchita Shrestha[SUP] 7 [/SUP], Renato Santana de Aguiar[SUP] 8 [/SUP], Elizabeth M Batty[SUP] 2 [/SUP], Mauro M Teixeira[SUP] 9 [/SUP], Abhilasha Karkey[SUP] 7 [/SUP], Elizabeth A Ashley[SUP] 10 [/SUP], Poj Intalapaporn[SUP] 11 [/SUP], Viravarn Luvira[SUP] 12 [/SUP], Weerapong Phumratanaprapin[SUP] 12 [/SUP], Kesinee Chotivanich[SUP] 13 [/SUP], Mallika Imwong[SUP] 14 [/SUP], Nicholas J White[SUP] 2 [/SUP]; AD ASTRA Collaborative Group
Affiliations
- PMID: 42520824
- DOI: 10.1016/S1473-3099(26)00255-0
Background: The oral antiviral therapies baloxavir marboxil (hereafter baloxavir), favipiravir, and oseltamivir have not been simultaneously compared for the treatment of seasonal influenza. We aimed to determine their relative efficacies in accelerating viral clearance in patients with symptomatic influenza virus infection at low risk of progression to severe disease.
Methods: We conducted a phase 2, open-label, randomised, controlled, adaptive platform trial in patients aged 18-60 years in Thailand, Laos, Nepal, and Brazil, recruited in four hospital outpatient or primary care departments with acute influenza (≤ 4 days of symptoms) and a low risk of progression to severe disease. Patients were randomly assigned 1:1:1:1:1 using a centralised online app to receive baloxavir (single oral dose of 40 mg if bodyweight <80 kg or 80 mg if bodyweight ≥80 kg), favipiravir (oral loading dose of 1800 mg, followed by 1800 mg 12 h later, and then 800 mg twice daily for 4 days), oseltamivir (oral dose 75 mg twice daily for 5 days), no study drug, or another ongoing intervention (reported separately). Randomisation was stratified by site and used block sizes of 15. The primary endpoint was the rate of oropharyngeal influenza viral RNA clearance, estimated under a Bayesian hierarchical linear model fitted to the daily log[SUB]10[/SUB] oropharyngeal viral densities from day 0 to day 5. Analyses were conducted in the modified intention-to-treat population (mITT), defined as patients with PCR-confirmed influenza with more than 250 viral RNA copies per mL at randomisation. Intervention groups were assessed for superiority over the no study drug group (posterior probability >0·9 that the relative increase in viral clearance was ≥20%); if superiority was met, intervention groups were assessed for non-inferiority relative to baloxavir (posterior probability >0·9 that the relative reduction in viral clearance was ≤10%). Secondary outcomes included time to resolution of fever and time to resolution of all symptoms. The trial is registered with ClinicalTrials.gov (NCT05648448) and is ongoing.
Findings: Between Feb 22, 2023, and Dec 12, 2025, 944 patients with influenza virus infection were randomly assigned to baloxavir (n=199; mITT 163 [82%]), favipiravir (n=223; mITT 196 [88%]), oseltamivir (n=200; mITT 170 [85%]), no study drug (n=228; mITT 200 [88%]) or other interventions (n=94). 120 patients were excluded based on baseline viral density (≤250 copies per mL), and one participant withdrew before collection of quantitative PCR results on day 0. 457 (63%) patients in the mITT population were female and 272 (37%) were male. Compared with no study drug, viral clearance rates were accelerated by 86% (95% credible interval [CrI] 60-117) with baloxavir, 66% (45-94) with favipiravir, and 49% (28-74) with oseltamivir. For all interventions, the posterior probability that the relative increase in viral clearance was 20% or more was 1·0. Compared with baloxavir, oseltamivir was inferior (20% slower clearance, 95% CrI 6 to 32; posterior probability 0·93 that the relative reduction in viral clearance was <10%); non-inferiority could not be shown for favipiravir (10% slower clearance, 95% CrI -4 to 22; posterior probability 0·55 that the relative reduction in viral clearance was <10%). Median time to fever resolution was accelerated with all three antivirals compared with no study drug (absolute differences ranging from 0·5 days to 0·9 days), whereas time to resolution of all symptoms was not significantly different between groups. 31 adverse events of grade 3 or above occurred, five of which were considered severe (one in the favipiravir group, one in the oseltamivir group, and three in the no study drug group).
Interpretation: Oral baloxavir, favipiravir, and oseltamivir accelerated influenza viral clearance rates in adults with early non-severe seasonal influenza at low risk of progression to severe disease. Baloxavir had the greatest in-vivo antiviral efficacy, followed by favipiravir and oseltamivir. These antivirals shortened fever duration but showed no clear effects on time to complete symptom resolution. This pharmacometric approach can inform prioritisation of antiviral agents for further study and potential inclusion in pandemic stockpiles.
Funding: Wellcome Trust.